SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
A 130 / 30 Global Pharma ETF Strategy
PFE
|
|
|
-9.45%
in
20 days
<> Investors who are bullish on the generic drug industry may consider implementing a 130 / 30 global pharma investing strategy through equal-weight (5% each) short positions for the six brand drug companies outlined below with 30% of their assets while investing 130% of assets in long positions among generic drug makers. The list of brand drug companies with significant patent expiration exposure over the next 2-3 years includes Pfizer (NYSE: PFE ), GlaxoSmithKline (NYSE: GSK ), Takeda Pharma (OTC: TKPHY.PK ), Sanofi-Aventis ( SNY ), AstraZeneca ( AZN ), and Merck ( MRK ).
...
|
Pfizer Inc
PFE
|
|
|
+4.45%
in
516 days
Pfizer (PFE)
Click Here for the Strategy Report on this major drug manufacturer company
Stocks Covered: Pfizer (PFE)
Target Returns: 7.56% or 15.33% Annualized *
Downside Protection: Up to 6.12%
Duration: 180 Days
Investor Level: Beginner to Advanced
Risk Level: Moderate Relative Risk
<> <> Analysts'
Recommendation: | Buy | <> <> <> <><><><>< /><><><><><><><><><><><><><><><><><><><><><><><><>< />< />< />< />< />< /><>< />...
|
FDA, Clinical Trial Calendar Updates: Weight Loss, Diabetes, and More
PFE
|
|
|
+20.76%
in
217 days
(closed on 11/04/09)
<> The FDA Calendar includes companies with pending new drug, biological agent, or medical device new product decisions at the FDA sorted by their PDUFA deadline dates. The entries are updated on a daily basis as new information becomes available with a total of 110 entries through 4/1/09. The FDA Calendar includes the following information: company name, ticker, decision d...
|
Pfizer
PFE
|
|
|
+33.50%
in
242 days
Pfizer has lost a lot of market share. It's dividend yield is almost 10%, and has a low pe. It is going to move up.
|
Big Pharma Goes Generic
PFE
|
|
|
-6.13%
in
34 days
(closed on 04/01/09)
<> <> <> <> <> <>  Sanofi-Aventis (SNY) is now the 11 th largest generic drug maker in the world following its successful acquisition of Czech generic drug company Zentiva. As $70B in brand drug patents are set to expire through 2012, big pharma companies are hedging their bets through generic drug divisions, including Pfizer (PFE) - Greenstone, Novartis (NVS) - Sandoz, and the recently announced Merck (MRK) BioVent...
|
From the Blogosphere
Good News for Bristol-Myers – Analyst Blog
|
|
|
Recently, Bristol-Myers Squibb Co. (BMY) received approval from the U.S. Food and Drug Administration (FDA) to market Abilify (aripiprazole) for the treatment of irritability in pediatric patients having autistic disorder. Abilify can be used to treat children aged 6 to 17 years for symptoms of aggression toward others, deliberate self injury, temper tantrums and quick mood swings.
Bristol-Myers and Otsuka Pharmaceutical Co. jointly develop and distribute the drug in the U.S. and Europe. The FDA approval of Abilify for treating irritation in pediatric patients with autistic disorder is bas...
|
Cramer on BloggingStocks: Sanofi has lots of upside catalysts
Filed under: Analyst reports, Pfizer (PFE), Market matters, Bristol-Myers Squibb (BMY), Merck and Co (MRK), Lilly (Eli) (LLY), Deere and Co (DE), Stocks to Buy, Potash Corp. of Saskatchewan (POT) TheStreet.com's Jim Cramer says it looks like the patent worries aren't so dire after all.
Now that we see that health care reform is not going to bring price caps or socialization of medicine, we are beginning to see some real expansion in the drug stocks, including Merck (MRK) (<>Cr...
|
Panel Backing for Prevnar 13 – Analyst Blog
|
|
|
Pfizer (PFE) announced that the US Food and Drug Administration’s (FDA) Vaccines and Related Biological Products advisory committee voted in favor (10 to 1) of data presented to support the safety and effectiveness of Prevnar 13, its 13-valent pneumococcal conjugate candidate vaccine. The favorable recommendation of the vaccine was based on data from 13 phase III studies carried out on more than 7,000 children.
Pfizer is seeking FDA approval for the vaccine to prevent diseases (including sepsis, meningitis, bacteremia, bacteremic pneumonia, and empyema caused by 13 Streptococcus pneumoni...
|
MDVN Starts New Alzheimer’s Trials – Analyst Blog
|
|
|
Earlier this month, Medivation, Inc. (MDVN) and Pfizer, Inc. (PFE) initiated two phase III studies, CONTACT and CONSTELLATION, with Dimebon in patients with moderate-to-severe Alzheimer's disease (AD). Dimebon is being developed in collaboration with Pfizer for the treatment of Alzheimer’s and Huntington diseases.
The CONTACT study will assess the potential benefits of adding Dimebon to ongoing treatment with Pfizer’s Aricept on neuropsychiatric symptoms and activities of daily living. Meanwhile, the CONSTELLATION study will evaluate the effects of adding Dimebon to Forest Lab’s (FRX) ...
|
Minyanville.: Our Economy is on Steroids
|
|
|
Below is a guest post, reprinted with permission of author Vitaliy Katsenelson who writes often at Minyanville.com. I don't have as much time to read the site as I used to, but he is definitely one of the more thought provoking writers at the site.
If you are new to FMMF, I wanted to bring over Vitaliy's piece because it summarizes what you can find in hundreds of previous pieces we've written; summarized in one location. Vitaliy is more generous than I, calling this the economy on steroids... injected by our doctors. I've likened them more to drug dealers, and America akin to drivin...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
|
|
|
|
tanumoy
(+103.85% risk: conservative)
|
|
|
Portfolio results thru 8/8/08
- Portfolio at www.updown.com - started 1/11/08
9.8% return includes dividends and commission.
Started socialpicks on 6/30. some stocks here are not in...
|
More Resources
|
About Pfizer Inc
- Answers.com
